- BioCryst Pharmaceuticals Inc BCRX has withdrawn its proposed public offering of $200 million of its stock and pre-funded warrants.
- The Company says that it is well-capitalized, with cash, cash equivalents, restricted cash, and investments of $222.8 million as of June 30, 2021.
- Based on expectations for revenue, operating expenses, and the option to access an additional $75 million from the existing credit facility, BCRX believes current cash runway into 2023.
- Price Action: BCRX shares are up 8.45% at $16.49 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
